Literature DB >> 24508128

The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.

Ryan C Conyers1, Jennifer R Mazzone1, Maxime A Siegler1, Abhai K Tripathi2, David J Sullivan2, Bryan T Mott1, Gary H Posner3.   

Abstract

Sixteen new artemisinin-derived 2-carbon-linked trioxane dimers were prepared to study chemical structure/antimalarial activity relationships (SAR). Administering a very low single oral dose of only 5mg/kg of dimer secondary alcohol 6a or 6b plus 15 mg/kg of mefloquine hydrochloride prolonged the lives of Plasmodium berghei-infected mice to an average of 25 days after infection. This ACT chemotherapy result is of high medicinal significance because the antimalarial efficacy of the popular trioxane drug artemether (2) plus mefloquine under the same conditions was significantly lower (only 20 day average survival). NH-aryl carbamate derivatives 7e, 7i, and 7j of 2-carbon-linked dimer alcohol 6b also significantly outperformed artemether (2) in prolonging the survival times (25-27 days) of malaria-infected mice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimalarial chemotherapy; Oral bioavailability; Single oral dose ACT; Trioxane dimer carbamates

Mesh:

Substances:

Year:  2014        PMID: 24508128      PMCID: PMC3943161          DOI: 10.1016/j.bmcl.2014.01.059

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

1.  Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity.

Authors:  Peter Gibbons; Edite Verissimo; Nuna C Araujo; Victoria Barton; Gemma L Nixon; Richard K Amewu; James Chadwick; Paul A Stocks; Giancarlo A Biagini; Abhishek Srivastava; Philip J Rosenthal; Jiri Gut; Rita C Guedes; Rui Moreira; Raman Sharma; Neil Berry; M Lurdes S Cristiano; Alison E Shone; Stephen A Ward; Paul M O'Neill
Journal:  J Med Chem       Date:  2010-10-27       Impact factor: 7.446

2.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

3.  Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria.

Authors:  Jin Guo; Armand W Guiguemde; Annael Bentura-Marciano; Julie Clark; Richard K Haynes; Wing-Chi Chan; Ho-Ning Wong; Nicholas H Hunt; R Kiplin Guy; Jacob Golenser
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

4.  A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.

Authors:  Steven J Burgess; Audrey Selzer; Jane Xu Kelly; Martin J Smilkstein; Michael K Riscoe; David H Peyton
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

5.  A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice.

Authors:  Deuk Kyu Moon; Abhai Tripathi; David Sullivan; Maxime A Siegler; Sean Parkin; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2010-09-29       Impact factor: 2.823

6.  Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells.

Authors:  Andrew S Rosenthal; Xiaochun Chen; Jun O Liu; Diana C West; Paul J Hergenrother; Theresa A Shapiro; Gary H Posner
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

7.  New bis-thiazolium analogues as potential antimalarial agents: design, synthesis, and biological evaluation.

Authors:  Sergio A Caldarelli; Siham El Fangour; Sharon Wein; Christophe Tran van Ba; Christian Périgaud; Alain Pellet; Henri J Vial; Suzanne Peyrottes
Journal:  J Med Chem       Date:  2013-01-04       Impact factor: 7.446

8.  Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum.

Authors:  Nicanor Obaldia; Barbara M Kotecka; Michael D Edstein; Richard K Haynes; Burkhard Fugmann; Dennis E Kyle; Karl H Rieckmann
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

9.  Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.

Authors:  Richard K Amewu; James Chadwick; Afthab Hussain; Somnath Panda; Rinki Rinki; Omar Janneh; Stephen A Ward; Candel Miguel; Hollie Burrell-Saward; Livia Vivas; Paul M O'Neill
Journal:  Bioorg Med Chem       Date:  2013-10-01       Impact factor: 3.641

10.  Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial.

Authors:  Emmanuelle Espié; Angeles Lima; Benjamin Atua; Mehul Dhorda; Laurence Flévaud; Eric M Sompwe; Pedro Pablo Palma Urrutia; Philippe J Guerin
Journal:  Malar J       Date:  2012-05-25       Impact factor: 2.979

View more
  2 in total

1.  Antimalarial chemotherapy: artemisinin-derived dimer carbonates and thiocarbonates.

Authors:  Jennifer R Mazzone; Ryan C Conyers; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2014-04-16       Impact factor: 2.823

2.  Antimalarial chemotherapy: orally curative artemisinin-derived trioxane dimer esters.

Authors:  Ryan C Conyers; Jennifer R Mazzone; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2014-11-27       Impact factor: 2.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.